Muscle Relaxant Drugs Market Analysis

Therapeutic Group (Neuromuscular Blockers, Spasmolytic)

The global muscle relaxant market is segmented and analyzed for demand and supply by therapeutic group into neuromuscular blockers and spasmolytics. Amongst these segments, the neuromuscular blockers segment is anticipated to garner the largest revenue by the end of 2037, backed by the growing number of patients with neuromuscular disorders worldwide, with increasing number of people working remotely. According to the data, between 2019 and 2021, approximately 13 million people were registered every year for neuromuscular diagnosis in the United Kingdom.

Our in-depth analysis of the global muscle relaxant drugs market includes the following segments:

By Therapeutic Group	Neuromuscular Blockers Spasmolytic
By Formulation	Cyclobenzaprine Carisoprodol Chlorzoxazone Metaxalone Methocarbamol Baclofen Tizanidine Orphenadrine Dantrolene
By Route of Administration	Oral Injectable Spray Ointment
By End-User	Hospital Pharmacy Retail Pharmacy Online Pharmacy

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of muscle relaxant drugs is estimated at USD 3.62 million.

The muscle relaxant drugs market size was valued at USD 3.43 million in 2024 and is poised to cross USD 8.06 million by the end of 2037, registering more than 6.9% CAGR during the forecast period i.e., between 2025-2037. Upsurge in the use of muscle relaxants with other anaesthetics during surgical procedures, increasing sedentary lifestyle and decreasing levels of activity will boost the market growth.

North America is likely to dominate majority industry share by 2037, driven by upsurge in healthcare expenditure, low physical activity along with the high prevalence of musculoskeletal conditions affecting people of all ages in the region.

The major players in the market include AbbVie Inc., Antisense Therapeutics Limited, Sandoz International GmbH, Abbott Laboratories, Pfizer, Inc., Merck & Co., Inc., SteriMax Inc., Vertical Pharmaceuticals, LLC, Instas Pharmaceuticals Ltd., F. Hoffmann-La Roche Ltd.

Muscle Relaxant Drugs Market Analysis